Aristides Capital LLC Buys 6,850 Shares of Kamada Ltd. (NASDAQ:KMDA)

Aristides Capital LLC lifted its position in Kamada Ltd. (NASDAQ:KMDA) by 12.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 63,485 shares of the biotechnology company’s stock after purchasing an additional 6,850 shares during the quarter. Aristides Capital LLC owned about 0.11% of Kamada worth $387,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in KMDA. Public Employees Retirement System of Ohio purchased a new position in Kamada during the 3rd quarter valued at approximately $77,000. JPMorgan Chase & Co. purchased a new position in shares of Kamada in the fourth quarter valued at $67,000. Finally, Geode Capital Management LLC increased its position in Kamada by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 1,549 shares during the last quarter. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Kamada in a research report on Thursday, March 6th. Benchmark started coverage on shares of Kamada in a report on Friday, March 21st. They issued a “buy” rating and a $15.00 price target for the company. Finally, StockNews.com cut Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, March 25th.

Kamada Trading Down 4.6 %

Shares of KMDA opened at $5.99 on Friday. The company’s fifty day simple moving average is $7.09 and its 200-day simple moving average is $6.35. The company has a market cap of $344.31 million, a P/E ratio of 21.39, a P/E/G ratio of 0.97 and a beta of 0.97. Kamada Ltd. has a twelve month low of $4.74 and a twelve month high of $9.16.

Kamada Dividend Announcement

The firm also recently announced a — dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be paid a dividend of $0.20 per share. The ex-dividend date of this dividend is Monday, March 17th.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.